Skip to main content
OpenTrials
Completed

NCT Number: NCT00925743

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

This study is designed as a phase 1, multicenter, open-label, single arm, dose-escalation, study of Cabazitaxel in combination with cisplatin, to determine safety, pharmacokinetics (PK), and efficacy in solid tumors (parts 1 and 2) and single sequence, two-treatment, crossover studies to determine the effect of strong CYP3A4 inhibition and induction on the PK of Cabazitaxel in patients with solid tumors (part 3 and part 4, respectively).

There are 4 parts to the study:

Part 1: Determine the Dose Limiting Toxicities (DLT)'s and Maximum Tolerated Dose (MTD) based on safety.

Part 2: Determine the anti-tumor activity of the combination regimen at the Maximum Tolerated Dose (MTD) in an extended cohort of patients.

Part 3: Determine the effect of a strong CYP3A4 inhibitor (ketoconazole) on the pharmacokinetic (PK) of Cabazitaxel.

Part 4: Determine the effect of a strong CYP3A4 inducer (rifampin) on the pharmacokinetic (PK) of Cabazitaxel.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Investigational Site Number 840008, Los Angeles, California, United States

Loading trial locations.

About this study

The total duration on the study per subject will be about 26 weeks broken down as follows:

  • A maximum of 21-day screening phase,
  • 21-days (+/- 2 weeks) study treatment cycles,
  • 30-day follow-up visit after the last dose of study medication.
  • Cut-off date for parts 1, 2, 3 and 4: when the last patient has completed 6 cycles (parts 1 and 2) or 2 cycles (parts 3 and 4) of treatment or discontinued study treatment (for disease progression, unacceptable toxicity, withdrawal of consent, or investigator's decision to withdraw), whichever comes first, in the corresponding part.

Patients still receiving treatment at the cut-off date may continue to receive treatment beyond the cut-off date at investigator's discretion if benefiting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • confirmed metastatic or unremovable advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist, but for which cisplatin based therapy is appropriate
  • signed informed consent

Exclusion criteria

  • limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale)
  • inability to follow study requirements and schedule
  • treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other cancer therapy
  • serious medical illness at same time of study and/or significantly abnormal lab reports
  • lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding.
  • Women of childbearing potential not protected by highly effective contraceptive method of birth control OTHER than hormonal contraception (Part 4 only).
  • prior significant hearing or kidney problems
  • continued toxic effects of prior chemotherapy
  • cancers that cannot be physically measured (Part 2 only)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

Cabazitaxel (XRP6258)

Drug
  • administered by IV infusion
  • in addition to cisplatin treatment

Primary outcomes

  1. Dose Limiting Toxicities (DLT)'s of the combination of cabazitaxel and cisplatin (part 1)

    Time frame: first cycle (i.e.3 weeks)

  2. Objective response ratio (Complete response (CR) and partial response (PR)) (part 2)

    Time frame: up to 6 cycles, ie 18 weeks

  3. Pharmacokinetics (PK) of cabazitaxel (part 3 and 4)

    Time frame: up to 6 cycles, ie 18 weeks

Secondary outcomes

  1. Time to progression (TTP) (part 1 and 2)

    Time frame: up to 6 cycles, ie 18 weeks

  2. Duration of response (DR) (Part 1 and 2)

    Time frame: up to 6 cycles, ie 18 weeks

  3. Cabazitaxel pharmacokinetic (part 1 and 2)

    Time frame: up to 6 cycles, ie 18 weeks

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

A Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Cabazitaxel In Combination With Cisplatin Administered Every 3 Weeks In Subjects With Advanced Solid Malignancies

Important dates

Study start
2009
Primary completion
2013
Study completion
2013
First posted
Jun 22, 2009
Registry last updated
May 16, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.